MX379386B - Proceso de glicoconjugación. - Google Patents

Proceso de glicoconjugación.

Info

Publication number
MX379386B
MX379386B MX2018015658A MX2018015658A MX379386B MX 379386 B MX379386 B MX 379386B MX 2018015658 A MX2018015658 A MX 2018015658A MX 2018015658 A MX2018015658 A MX 2018015658A MX 379386 B MX379386 B MX 379386B
Authority
MX
Mexico
Prior art keywords
glycoconjugates
methods
immunogenic compositions
glycoconjugation
oxidant
Prior art date
Application number
MX2018015658A
Other languages
English (en)
Inventor
Avvari Krishna Prasad
Jin- Hwan Kim
Mingming Han
Rajesh Kumar Kainthan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX379386B publication Critical patent/MX379386B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para preparar glicoconjugados que contienen un sacárido conjugado a una proteína portadora por medio del uso de un agente/oxidante relacionado con un radical nitroxilo estable como un agente oxidante, a composiciones inmunogenicas que comprenden tales glicoconjugados, y a métodos para el uso de tales glicoconjugados y composiciones inmunogenicas.
MX2018015658A 2012-12-20 2013-12-13 Proceso de glicoconjugación. MX379386B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740311P 2012-12-20 2012-12-20
PCT/IB2013/060933 WO2014097099A2 (en) 2012-12-20 2013-12-13 Glycoconjugation process

Publications (1)

Publication Number Publication Date
MX379386B true MX379386B (es) 2025-03-11

Family

ID=50070610

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008027A MX363512B (es) 2012-12-20 2013-12-13 Proceso de glicoconjugacion.
MX2018015658A MX379386B (es) 2012-12-20 2013-12-13 Proceso de glicoconjugación.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015008027A MX363512B (es) 2012-12-20 2013-12-13 Proceso de glicoconjugacion.

Country Status (21)

Country Link
US (5) US10392420B2 (es)
EP (3) EP3363806B1 (es)
JP (2) JP6502262B2 (es)
KR (2) KR101980989B1 (es)
CN (3) CN106177933B (es)
AU (2) AU2013365873B2 (es)
BR (2) BR112015015031B1 (es)
CA (2) CA2893343C (es)
DK (2) DK2935299T3 (es)
ES (2) ES2755082T3 (es)
FI (1) FI3363806T3 (es)
FR (2) FR22C1038I2 (es)
HR (1) HRP20221438T1 (es)
HU (2) HUE060718T2 (es)
IL (2) IL274500B2 (es)
MX (2) MX363512B (es)
PL (2) PL2935299T3 (es)
PT (2) PT2935299T (es)
RU (1) RU2672053C2 (es)
SI (2) SI2935299T1 (es)
WO (1) WO2014097099A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3206112A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP6612260B2 (ja) * 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX371453B (es) * 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
ES2865485T3 (es) 2014-05-24 2021-10-15 Biological E Ltd Nueva vacuna de conjugado meningocócico semisintético
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
EP3325008B1 (en) * 2015-07-21 2025-09-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MY187472A (en) * 2015-09-10 2021-09-23 Inventprise Llc Multivalent vlp conjugates
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3181148A1 (en) * 2015-12-17 2017-06-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against streptococcus pneumoniae serotype 2
EP3331556B8 (en) * 2015-12-17 2019-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against streptococcus pneumoniae serotype 2
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3634481A4 (en) 2017-06-10 2021-07-21 Inventprise, LLC. MULTIVALENT CONJUGATE VACCINES WITH BIVALENT OR MULTIVALENT CONJUGATE POLYSACCHARIDES THAT CONFIRM ENHANCED IMMUNOGENICITY AND AVIDITY
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US20210177957A1 (en) 2017-12-06 2021-06-17 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN109879967A (zh) * 2017-12-15 2019-06-14 苏州和锐生物科技有限公司 一种乙酰氨基葡萄糖偶联物的制备方法及应用
AU2019239890B2 (en) * 2018-03-23 2025-01-30 Koranex Capital Precision glycoconjugates as therapeutic tools
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
CN112074293B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112021005425A2 (pt) * 2018-09-23 2021-06-15 Biological E Limited polissacarídeos capsulares purificados de streptococcus pneumoniae
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021373358B2 (en) 2020-11-04 2026-01-08 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) * 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
CN115721710A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗组合物
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) * 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4713008A2 (en) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120682395B (zh) * 2025-08-20 2025-11-07 复星安特金(成都)生物制药有限公司 一种活化细菌荚膜多糖的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU8070898A (en) 1997-06-12 1998-12-30 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacteri al host
KR20010071212A (ko) 1998-05-07 2001-07-28 추후보정 일차 알콜의 선택적 산화 반응
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1149846B1 (en) 2000-04-25 2003-09-10 SCA Hygiene Products Zeist B.V. Oxidation of polysaccharides with nitroxyls
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
WO2004041157A2 (en) * 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
US9296795B2 (en) 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2005024038A2 (en) * 2003-09-11 2005-03-17 Nederlands Vaccininstituut Process for producing a capsular polysaccharide for use in conjugate vaccines
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007023386A2 (en) * 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN103251940A (zh) * 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
BRPI1014494A2 (pt) * 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
CN101590224A (zh) * 2009-06-30 2009-12-02 广州精达医学科技有限公司 高效14价肺炎球菌结合疫苗
ES2812523T3 (es) * 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
CZ302503B6 (cs) * 2009-12-11 2011-06-22 Contipro C A.S. Zpusob prípravy derivátu kyseliny hyaluronové oxidovaného v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd a zpusob jeho modifikace
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
US20140141032A1 (en) * 2012-11-20 2014-05-22 Patricia Guerry TEMPO-mediated glycoconjugation of immunogenic composition against Campylobacter jejuni with improved structural integrity and immunogenicity

Also Published As

Publication number Publication date
PT2935299T (pt) 2019-11-19
CA2943263A1 (en) 2014-06-26
US11603384B2 (en) 2023-03-14
WO2014097099A2 (en) 2014-06-26
IL239430B (en) 2020-07-30
DK3363806T3 (da) 2022-11-21
US12234259B2 (en) 2025-02-25
EP3363806B1 (en) 2022-11-16
AU2013365873A1 (en) 2015-06-04
SI3363806T1 (sl) 2023-04-28
CN106177933B (zh) 2020-09-29
AU2013365873B2 (en) 2018-04-05
KR20170087540A (ko) 2017-07-28
AU2018204421B2 (en) 2019-10-31
HK1213267A1 (zh) 2016-06-30
CN108524931A (zh) 2018-09-14
PL2935299T3 (pl) 2020-05-18
BR122020000550B1 (pt) 2021-12-07
HUE060718T2 (hu) 2023-04-28
US20210371453A1 (en) 2021-12-02
US20200331959A1 (en) 2020-10-22
HUE060718T4 (hu) 2023-03-28
KR101980989B1 (ko) 2019-05-21
HRP20221438T1 (hr) 2023-02-03
CN106177933A (zh) 2016-12-07
EP2935299B1 (en) 2019-10-02
IL274500B1 (en) 2023-09-01
FI3363806T3 (fi) 2023-01-31
WO2014097099A3 (en) 2014-11-06
KR101787217B1 (ko) 2017-10-18
AU2018204421A1 (en) 2018-07-05
JP6502262B2 (ja) 2019-04-17
JP6686057B2 (ja) 2020-04-22
JP2016509081A (ja) 2016-03-24
MX2015008027A (es) 2016-03-07
US10745438B2 (en) 2020-08-18
HK1231412A1 (zh) 2017-12-22
CA2893343C (en) 2019-05-14
RU2672053C2 (ru) 2018-11-09
IL274500A (en) 2020-06-30
SI2935299T1 (sl) 2019-12-31
HUE047120T2 (hu) 2020-04-28
JP2018127632A (ja) 2018-08-16
ES2933127T3 (es) 2023-02-01
US20190330265A1 (en) 2019-10-31
CN108524931B (zh) 2023-02-03
EP4169929A1 (en) 2023-04-26
IL239430A0 (en) 2015-07-30
IL274500B2 (en) 2024-01-01
PL3363806T3 (pl) 2022-12-19
CA2943263C (en) 2018-12-04
US11117928B2 (en) 2021-09-14
CA2893343A1 (en) 2014-06-26
FR22C1038I1 (fr) 2022-09-09
FR23C1021I1 (fr) 2023-06-30
KR20150085070A (ko) 2015-07-22
US10392420B2 (en) 2019-08-27
RU2015121494A (ru) 2017-01-25
PT3363806T (pt) 2022-12-16
BR112015015031B1 (pt) 2020-07-14
EP2935299A2 (en) 2015-10-28
US20150328328A1 (en) 2015-11-19
CN104870463A (zh) 2015-08-26
MX363512B (es) 2019-03-26
CN104870463B (zh) 2018-09-28
FR22C1038I2 (fr) 2023-05-26
DK2935299T3 (da) 2019-11-18
EP3363806A1 (en) 2018-08-22
ES2755082T3 (es) 2020-04-21
BR112015015031A2 (pt) 2017-07-11
US20230203091A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX379386B (es) Proceso de glicoconjugación.
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
PH12013502284A1 (en) Protein-active agent conjugates and method for preparing the same
NZ597517A (en) 5-fluoropyrimidinone derivatives
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
IN2014DN06104A (es)
MX359318B (es) Composiciones que comprenden polietilenglicol y ascorbato.
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MX338828B (es) Lote maestro y proceso para la preparacion de una composicion polimerica.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2014004920A (es) Nuevos derivados de pirazina.
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
MX358132B (es) Solucion de trombina y metodos de uso de esta.
CA2800424C (en) B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells
MX336369B (es) Uso de acido elagico como agentes anticaspa.
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12015500262A1 (en) Novel pyridine derivatives
MX351093B (es) Nuevos derivados de azetidina.